Alpha Teknova, Inc. revenue
Alpha Teknova, Inc.'s revenue was $40.5m in fiscal 2025, up 7.4% on the year before. Since fiscal 2020 ($31.3m) it has grown at a compound 5.3% a year. Over the last twelve months it was $43.7m.
Revenue history
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Lab Essentials | $31M | 76.6% | ▲ 7.5% |
| Clinical Solutions | $7.7M | 18.9% | ▲ 7.8% |
| Other Product | $1.8M | 4.5% | ▲ 3.5% |
| Region | Revenue | Share | YoY |
|---|---|---|---|
| United States | $38.2M | 94.4% | ▲ 6.5% |
| Outside the US | $2.3M | 5.6% | ▲ 24.4% |
From Alpha Teknova, Inc.'s 10-K filed March 2, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Alpha Teknova, Inc. | $43.7m | 12.3% | 3.7% |
| Omniab, Inc. | $40.2m | 90.6% | -14.7% |
| Rapid Micro Biosystems, Inc. | $35.2m | 16.1% | 22.5% |
| Champions Oncology, Inc. | $60.7m | 6.7% | 4.8% |
| Precipio, Inc. | $60.8m | 29.5% | 43.6% |
| 908 Devices Inc. | $60.8m | 13.4% | 7.5% |
Compare with peers
- Omniab, Inc. revenue
- Rapid Micro Biosystems, Inc. revenue
- Champions Oncology, Inc. revenue
- Precipio, Inc. revenue
- 908 Devices Inc. revenue
Head to head: OABI vs TKNORPID vs TKNOCSBR vs TKNO
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies